Recent Updates on Management of Diffuse Large B-Cell Lymphoma
EP. 1: Treating Newly Diagnosed Patients With DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.
EP. 2: Treatment Considerations in DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.
EP. 3: DLBCL: Approaching CNS Prophylaxis
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health A panel of experts explain how they approach CNS prophylaxis in DLBCL.
EP. 4: Outlook for CNS Lymphoma
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.
EP. 5: Managing Relapsed DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.
EP. 6: Recommendations for Second-Line Therapy in DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.
EP. 7: Data From the L-MIND Trial
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).
EP. 8: DLBCL: Approaches to Treating Patients Ineligible for Transplant
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.
EP. 9: Newer Approvals for Previously Treated DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.
EP. 10: Recommendations for CAR T-Cell Therapy in R/R DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.
EP. 11: Evaluating CAR T Therapies in Lymphoma
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.
EP. 12: Optimal Approaches to Bridging Therapy in DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.
EP. 13: Treating Patients Post CAR T Therapy
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.
EP. 14: Looking at the Big Picture in DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.
EP. 15: Exploring Emerging Data in DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
